| |
 |
Capitalizing on New Opportunities for Stem Cell Products
|
Report #09-002
Publication Date: April 2009
Page Count: 263
Print Copy: $3,200
Company-wide Electronic Copy (includes print copy): $5,200
plus Data Set: an additional $1,200
|
As a result of the March 9, 2009 reversal of the 2001 restrictions on federal funding of human embryonic stem cell research, suppliers of stem cell related products are in need of a fast, accurate assessment of new opportunities in the stem cell products market. Capitalizing on New Opportunities for Stem Cell Products was designed to provide estimates on market share, projected growth of the stem cell research products market, types and species of stem cells scientists intend to use, suppliers – and level of satisfaction with – stem cell media, unmet product needs and more. Beyond providing an understanding of the current stem cell products market, this report will help identify the new/expanding stem cell research opportunities as a result of the change in the current administration’s policies regarding human embryonic stem cells research.
|
